Effect of TNF-α-Induced Sclerostin on Osteocytes during Orthodontic Tooth Movement by Fumitoshi Ohori, Hideki Kitaura, Aseel Marahleh, Akiko Kishikawa, Saika Ogawa, Jiawei Qi, Wei-Ren Shen, Takahiro Noguchi, Yasuhiko Nara, Itaru Mizoguchi

“…Osteocytes express receptor activator of nuclear factor kappa-B ligand (RANKL) and regulate osteoclast formation. …”
Get full text

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context by Abha A. Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte, Eric W. Winquist, Quincy Chu, Christian Kollmannsberger, Ralph Wong, Thierry Alcindor, Torsten O. Nielsen, Ming Tsao, Tricia R. Cottrell, Diane Provencher, John Hilton, Monika K. Krzyżanowska, Christine Elser, Sebastien Hotte, Joana Sederias, Siwei Zhang, Wei Tu, Janet Dancey

“…Summary: Background: Dual inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) has been shown to be an effective treatment strategy in many cancers. …”
Get full text

Spatiotemporal analysis of Plasmodium falciparum erythrocyte binding antigen-175 gene dimorphism in Ghana by Abraham Y. Kpirikai, Belinda A. Ofosu, Josie N. A. Okai, Victor Kornu, Abdul Rashid Kassim, Esther Donkor, Frederica Malm, Osumanu Ahmed, Mona-Liza E. Sakyi, Samirah Saiid, Albert Yao Kudakpo, Charles Mensah, Francis Dzabeng, Collins Morang’a, Gordon A. Awandare, Yaw Aniweh, Lucas N. Amenga-Etego

“…The merozoites stage of the parasite, crucial for asexual development invade erythrocytes through ligand-receptor interactions. Erythrocyte binding antigen (EBA)-175 is one of the key ligands facilitating invasion via interaction with glycoprotein A (GpA) receptors on the erythrocytes. …”
Get full text

Inhibition of platelet activation alleviates diabetes-associated cognitive dysfunction via attenuating blood-brain barrier injury by Fuxing Xu, Juan Hu, Xuying Li, Lan Yang, Shiqiu Jiang, Tao Jiang, Bo Cheng, Hailiang Du, Ruiduo Wang, Yingying Deng, Wei Gao, Yansong Li, Yaomin Zhu

“…Since platelets play an important role in regulating endothelial cell barrier function and over 95 % of the circulating soluble CD40 ligand (sCD40L) is derived from activated platelets, we speculated that the release of CD40L from activated platelets induced by diabetes was the key mechanism that aggravated BBB injury and leaded to DACD. …”
Get full text

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma by Solange Peters, Urania Dafni, Panagiota Zygoura, Sanjay Popat, Mary O'Brien, Rolf A Stahel, Alessandra Curioni-Fontecedro, Georges Coukos, Amy Roy, Riyaz Shah, Krisztian Homicsko, James Spicer, Stephen P Finn, David Gilligan, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Anthony Pope, Patricia Fisher, Sylvie Rusakiewicz, Ekaterina Fortis, Nesa Marti, Roswitha Kammler

“…Background Few tissue biomarkers exist to date that could enrich patient with cancer populations to benefit from immune checkpoint blockade by programmed cell death protein 1/ligand-1 (PD-/L-1) inhibitors. PD-L1 expression has value in this context in some tumor types but is an imperfect predictor of clinical benefit. …”
Get full text

Analysis of Genetic Variation in CD40 and CD40L: Relationship with mRNA Relative Expression and Soluble Proteins in Acute Coronary Syndrome by D. E. Martínez-Fernández, J. R. Padilla-Gutiérrez, F. Casillas-Muñoz, Emmanuel Valdés-Alvarado, Brenda Parra-Reyna, Maricela Aceves-Ramírez, J. F. Muñoz-Valle, U. Zalapa Flores, J. C. Chávez Herrera, Y. Valle

“…Acute coronary syndrome (ACS) can be triggered by the presence of inflammatory factors which promote the activation of immune cells by costimulatory molecules such as CD40 and its ligand CD40L. Environmental and genetic factors are involved in the etiology of the ACS. …”
Get full text

Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption by Morgane Lopez, Laurie Spehner, Fabrice André, Julien Viot, Evan Seffar, Amélie Marguier, Elsa Curtit, Guillaume Meynard, Erion Dobi, Sylvain Ladoire, Romain Boidot, Romain Loyon, Valentin Derangere, François-Clément Bidard, Christophe Borg, Laura Mansi, Marie Kroemer

“…In 40% of cases, a key mechanism of endocrine resistance to the standard first line is a mutation of the ligand-binding domain (LBD) of Estrogen Receptor 1 (ESR1) encoding estrogen receptor α (ER). …”
Get full text

CD21low B cells reveal a unique glycosylation pattern with hypersialylation and hyperfucosylation by Peter Tobias Felixberger, Peter Tobias Felixberger, Geoffroy Andrieux, Andrea Maul-Pavicic, Andrea Maul-Pavicic, Sigune Goldacker, Sigune Goldacker, Ina Harder, Ina Harder, Sylvia Gutenberger, Sylvia Gutenberger, Jonathan J. M. Landry, Vladimir Benes, Till Fabian Jakob, Melanie Boerries, Melanie Boerries, Lars Nitschke, Reinhard Edmund Voll, Reinhard Edmund Voll, Klaus Warnatz, Klaus Warnatz, Baerbel Keller, Baerbel Keller

“…This may implicate altered lectin-ligand interactions on the cell surface potentially affecting the CD21low B-cell function. …”
Get full text

Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors by Alissa J. Cooper, MD, Andrea Arfe, PhD, Biagio Ricciuti, MD, Andréanne Gagné, MD, PhD, Lynette M. Sholl, MD, Alessandro Di Federico, MD, Mark M. Awad, MD, PhD, Mihaela Aldea, MD, PhD, Maria Rosa Ghigna, MD, Miruna Grecea, MD, Phoebe Clark, MS, Jamie E. Chaft, MD, Mark G. Kris, MD, Gregory J. Riely, MD, Charles M. Rudin, MD, PhD, Ibiayi Dagogo-Jack, MD, Mari Mino-Kenudson, MD, Lingzhi Hong, MD, PhD, Neda Kalhor, MD, Natalie Vokes, MD, Anita Bowman, MS, Soo-Ryum Yang, MD, Natasha Rekhtman, MD, PhD, Adam J. Schoenfeld, MD

“…Nine (16%) of 55 tumor samples tested had programmed death-ligand 1 expression more than or equal to 50%, with 24 (44%) negative samples. …”
Get full text

Comparison of differences in transcriptional and genetic profiles between intra-central nervous system and extra-central nervous system large B-cell lymphoma by Shu Wang, Hong Chen, Bo Dai, Kang Zheng, Jiajun Zheng, Yuqi Zhu, Yan Yuan, Tianling Ding, Qian Wang, Liqian Xie, Rui Feng, Fengping Zhu, Jianbin Xiang, Weiqun Ding, Hong Ding, Yuan Li, Xiaodong Gu, Kunpeng Wu, Yifan Yuan, Jianping Song, Dongxiao Zhuang, Haoshu Zhong, Hanfeng Wu, Ying Mao, Tong Chen

“…Compared to SCNS-DLBCL and ecDLBCL, an immune-suppressive tumor microenvironment was observed in PCNS-DLBCL by analysis of immune-stimulating/inhibitory ligand‒receptor (L-R) pairs. By performing whole-exome sequencing in 93 patients, mutations enriched in BCR-NFkB and TLR pathways and the cooperation of these two pathways were found to be predominant in PCNS-DLBCL comparing to nonGCB-ecDLBCL. …”
Get full text

PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way by Wei Huang, Ji Zhou, Jia Li, Yakun Wan, Chao Hu, Meng Liu, Pan Xu, Feng Tang, Jianhua Sun, Xiaolu Yu, Yiru Long, Binfan Chen, Yongliang Tong, Mengwen Shan, Xiaomin Jia, Henglei Lu, Runqiu Chen, Jin Ren, Guangyi Jin, Likun Gong

“…Here, we aimed to improve efficacy for anti-programmed death ligand 1 (PD-L1) therapy by developing a PD-L1/TLR7 dual-targeting nanobody-drug conjugate (NDC), based on the PD-L1 nanobodies and TLR7 agonist we developed.Methods PD-L1 nanobodies were obtained by phage display screening and identified through T-cell activation bioassay, in vivo imaging and quantitative biodistribution study. …”
Get full text

RETRACTED: Mechanism of action of Asparagus officinalis extract against multiple myeloma using bioinformatics tools, in silico and in vitro study by Yanju Li, Xu Yang, Feiqing Wang, Feiqing Wang, Jianing Zhao, Chike Zhang, Dan Wu, Bo Yang, Rui Gao, Peng Zhao, Yun Zan, Min Su, Zhixu He, Yang Liu, Yang Liu, Yang Liu, Jishi Wang, Dongxin Tang

“…The latter showed that five core targets of the PI3K/AKT signaling pathway could bind to quercetin, among which EGFR, IL-6, and MYC showed strong docking, and the diosgenin ligand could bind to VEGFA. Cell experiments showed that asparagus, through the PI3K/AKT/NF-κB pathway, inhibited the proliferation and migration of MM cells, and caused retardation and apoptosis of MM cells in the G0/G1 phase.Discussion: In this study, the anti-cancer activity of asparagus against MM was demonstrated using network pharmacology, and potential pharmacological mechanisms were inferred using in vitro experimental data.…”
Get full text

SECTM1 acts as an immune-related biomarker of poor prognosis and promotes cancer progression by modulating M2 macrophage polarization in esophageal squamous cell carcinoma by Pengzhou Kong, Pengzhou Kong, Pengzhou Kong, Ye Jiao, Ye Jiao, Meng Sun, Meng Sun, Zhinan Zhou, Zhinan Zhou, Yingying Zhang, Yingying Zhang, Xin Yang, Xin Yang, Jing Ren, Jing Ren, Mengyuan Yang, Mengyuan Yang, Yanyan Dong, Yanyan Dong, Yanyan Dong, Bin Song

“…Furthermore, its overexpression promoted macrophage polarization towards the M2-like phenotype and promoted the migration of M2-like macrophage cells and C-C Motif Chemokine Ligand 5 (CCL5) was the key mediator in the pro-cancer effect of SECTM1. …”
Get full text

Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer by Jing Wang, Zhe Li, Wei Wang, Md Tauhidul Islam, Xiaoyan Wang, Zhen Han, Zihan Li, Guoxin Li, Yuming Jiang, Taojun Zhang, Wenjun Xiong, Zepang Sun, Lequan Yu, Zhicheng Zhang, Xianqi Yang, Shengtian Sang, Alyssa A Guo

“…The univariate Cox regression analysis revealed that the prediction signature of pathomics-driven ensemble model was a prognostic factor for progression-free survival in patients with gastric cancer who underwent immunotherapy (p<0.001, HR 0.35 (95% CI 0.24 to 0.50)), and remained an independent predictor after multivariable Cox regression adjusted for clinicopathological variables, (including sex, age, carcinoembryonic antigen, carbohydrate antigen 19-9, therapy regime, line of therapy, differentiation, location and programmed death ligand 1 (PD-L1) expression in all patients (p<0.001, HR 0.34 (95% CI 0.24 to 0.50)). …”
Get full text

Unveiling the toxicity of JWH-018 and JWH-019: Insights from behavioral and molecular studies in vivo and vitro by Fenghua Zhou, Yan Shi, Sujun Tan, Xiaoli Wang, Weicheng Yuan, Shuqi Tao, Ping Xiang, Bin Cong, Chunling Ma, Di Wen

“…Molecular docking identified essential residues PHE268, PHE170, and TRP279 within CB1R as pivotal contributors to enhancing receptor-ligand associations. While both drugs had a similar binding pattern with shared linker binding pockets in CB1R, there were still differences in their spatial conformation. …”
Get full text

Apaf-1 is an evolutionarily conserved DNA sensor that switches the cell fate between apoptosis and inflammation by Jie Ruan, Xuxia Wei, Suizhi Li, Zijian Ye, Linyi Hu, Ru Zhuang, Yange Cao, Shaozhou Wang, Shengpeng Wu, Dezhi Peng, Shangwu Chen, Shaochun Yuan, Anlong Xu

“…These findings suggest that Apaf-1 is an evolutionarily conserved DNA sensor and may serve as a cell fate checkpoint, which determines whether cells initiate inflammation or undergo apoptosis by distinct ligand binding.…”
Get full text

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y glo... by Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, Joachim G J V Aerts, Marina Garassino, Valter Torri, Solange Peters, Alex Friedlaender, Alfredo Addeo, Giuseppe Lo Russo, Roberto Ferrara, Diego Signorelli, Alessandro Russo, So Yeon Kim, Jarushka Naidoo, Scott Gettinger, Heather Wakelee, Martin Sebastian, Mark Awad, Abdul Rafeh Naqash, Alessio Cortellini, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Marco Russano, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Alain Gelibter, Giuseppe Tonini, Amin H Nassar, Alessandra Curioni-Fontecedro, Eleni Karapanagiotou, Emilio Bria, Jack Bell, Paolo Bironzo, Joao V Alessi, Alessandro Morabito, David J Pinato, Francesco Passiglia, Carlo Genova, Francesca Mazzoni, Alessandro Inno, Francesco Grossi, Luca Cantini, Lorenza Landi, Luigi Della Gravara, Margarita Majem, Uma Mukherjee, Federica Biello, Alessandro Leonetti, Annalisa Guida, Marianna Macerelli, Gabriele Minuti, Giulio Metro, Thomas Newsom-Davis, Eleni Josephides, Andrea Camerini, Elisa Roca, David O’Reilly, Mingjia Li, Laura Mezquita, Teresa Gorría, Claudia A M Fulgenzi, Lauren Young, Joel W Neal, Javier Baena, Francesco Pantano, Jacobo Rogado, Mary Jo Fidler, Teresa Beninato, Federica Pecci, Alessandro Di Federico, Kazuki Takada, Leonardo Brunetti, Talal El Zarif, Laura Moliner, Alberto Servetto, Sukumar Kalvapudi, Sai Yendamuri, Edoardo Garbo, Giuseppina Rita Di Fazio, Monica Loza, Ritujith Jayakrishnan, Michele Montrone, Nichola O Awosika, Bartlomiej Tomasik, Maximilian Rost, Isabelle Monnet, Francesco Agustoni, Artur Katz, Dwight Hall Owen, Michele Ghidini, Armida D’Incecco, Gianpaolo Spinelli, Monica Verrico, Manuel Dupont, Rafael Di Marco Barros, Diego Luigi Cortinovis, Chiara Bennati, Frank Aboubakar Nana, Anne-Marie Dingemans, Taher Abu Hejleh

“…Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. …”
Get full text

The PPAR Ω Pocket: Renewed Opportunities for Drug Development by Åsmund Kaupang, Trond Vidar Hansen

“…The past decade of PPARγ research has dramatically improved our understanding of the structural and mechanistic bases for the diverging physiological effects of different classes of PPARγ ligands. The discoveries that lie at the heart of these developments have enabled the design of a new class of PPARγ ligands, capable of isolating central therapeutic effects of PPARγ modulation, while displaying markedly lower toxicities than previous generations of PPARγ ligands. …”
Get full text

The Role of CXCR3 in Nervous System-Related Diseases by Fangyuan Wang, Bing Guo, Ziyang Jia, Zhou Jing, Qingyi Wang, Minghe Li, Bingqi Lu, Wulong Liang, Weihua Hu, Xudong Fu

“…The C-X-C chemokine receptor (CXCR) 3 and its ligands, C-X-C chemokine ligands (CXCLs), are widely expressed in both the peripheral nervous system (PNS) and central nervous system (CNS). …”
Get full text

Inhibitors of Human Dihydrofolate Reductase: A Computational Design and Docking Studies Using Glide by Lingala Yamini, Manga Vijjulatha

“…These newly designed ligands such as 14 -21 ,23 and 28 have shown good docking scores and predicted activities when compared to already existing ligands MTX and its analogues.…”
Get full text